Logo Image
News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademyShortsSponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos|
Clinical Operations & Strategy|
Patient Participation
Advertisement

Adrian Wildfire

Advertisement

Articles by Adrian Wildfire

Table7.8.png

Human Challenge Studies in Early Phase Antiviral Development

ByBruno Speder,Adrian Wildfire
July 8th 2015

Applied Clinical Trials

The concept of the human challenge model (HCM) originated from early societal attempts to halt the spread of acute diseases within their own communities

Advertisement

Latest Updated Articles

  • Table7.8.png
    Human Challenge Studies in Early Phase Antiviral Development

    July 8th 2015



Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market

2

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

3

ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch

4

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

5

Why Four Regulatory Scenarios Could De-Risk Selective Safety Data Collection

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us